Renaissance Technologies
UNCY icon

Renaissance Technologies’s Unicycive Therapeutics UNCY Stock Holding History

Renaissance Technologies’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,400
Closed -$161K – 3633
2026
Q1 		$161K Buy
+24,400
New +$160K ﹤0.01% 2954
2025
Q3 		– Sell
-11,790
Closed -$56.2K – 3947
2025
Q2 		$56.2K Buy
+11,790
New +$72.9K ﹤0.01% 3379
2024
Q3 		– Sell
-3,320
Closed -$16.6K – 3904
2024
Q2 		$16.6K Sell
3,320
-5,966
-64% -$58.7K ﹤0.01% 3399
2024
Q1 		$128K Buy
9,286
+5,877
+172% +$71.3K ﹤0.01% 3326
2023
Q4 		$30K Buy
+3,409
New +$22.3K ﹤0.01% 3534
2022
Q4 		– Sell
-1,290
Closed -$8K – 4430
2022
Q3 		$8K Buy
1,290
+190
+17% +$1.39K ﹤0.01% 3958
2022
Q2 		$9K Buy
+1,100
New +$10.5K ﹤0.01% 4161

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Renaissance Technologies's UNCY Position: Q2 2026 in Review

Renaissance Technologies sold out of Unicycive Therapeutics (UNCY) in Q2 2026, closing a stake of 24,400 shares — an estimated $161K sold.

Renaissance Technologies first reported a position in UNCY in Q2 2022 and held it in 7 quarters. The position peaked at $161K in Q1 2026. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Renaissance Technologies reported no remaining Unicycive Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Renaissance Technologies sold 24,400 Unicycive Therapeutics shares in Q2 2026, an estimated $161K.
  • Renaissance Technologies first reported a position in Unicycive Therapeutics in Q2 2022 and held it in 7 quarters.
  • Renaissance Technologies's Unicycive Therapeutics position peaked at $161K in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.